İlim IRMAK, Sılam BAŞ, Maide Gözde İNAM, Fatih TEKİN, Berkay YEŞİLYURT, Aziz Emre BİLGİN, Levent KILIÇ, Ömer KARADAĞ, Lütfi ÇÖPLÜ

Clinical Characteristics and Outcome of ANCA-Associated Vasculitis; Experience of A Single Reference Vasculitis Center

Objective: The aim of the study is to describe the clinical characteristics of Antineutrophil cytoplasmic antibodies-associated vasculitis and to analyze the parameters affecting the outcome. Materials and Methods: The study is a retrospective cohort study. Totally 130 patients with Antineutrophil cytoplasmic antibodies-associated vasculitis (18 years and over) who were followed up between October 2014 and October 2019 were analyzed. Demographic data, laboratory values, clinical course, thorax computed tomography findings and treatment approaches were noted from the charts of patients. Patients were divided into two groups as those with pulmonary involvement and non-pulmonary involvement. Results: We retrospectively reviewed the medical records of 130 patients with Antineutrophil cytoplasmic antibodies-associated vasculitis; 111 with granulomatosis with polyangiitis, 15 with microscopic polyangiitis, 1 with eosinophilic granulomatosis with polyangiitis, and 3 with other types of vasculitis. The ratio of having the abnormality in thoracic computed tomography was 72.2%. There were 84 cases with pulmonary involvement and 46 cases with non-pulmonary involvement. The frequency of microscopic polyangiitis was significantly higher (p=0.034) in non-pulmonary involvement cases. There were 67 cases with proteinase 3 Antineutrophil cytoplasmic antibodies and 39 cases with myeloperoxidase Antineutrophil cytoplasmic antibodies positivity. Most of the cases with proteinase 3 Antineutrophil cytoplasmic antibodies positivity were classified as granulomatosis with polyangiitis, this was statistically significant. Recovery was referenced for the outcome. Any of the variables were found statistically significant effective on outcome. Conclusions: Cases with pulmonary involvement were more than the cases without pulmonary involvement in our study. microscopic polyangiitis was significantly higher in non- pulmonary involvement cases. We studied on a large group, and these significant findings may have important implications for the investigation, pathogenesis, and treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis.

PDF

___

[1] Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013; 65: 1-11.

[2] Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum.1999; 42(3): 421-430.

[3] Lane SE, Watts RA, Shepstone L, et al. Primary systemic vasculitis: clinical features and mortality. QJM 2005; 98(2): 97-111.

[4] Frankel SK, Schwarz MI. The pulmonary vasculitides. Am J Respir Crit Care Med. 2012; 186(3): 216-224.

[5] Alba MA, Flores-Suárez LF, Henderson AG, et al. Interstital lung disease in ANCA vasculitis. Autoimmun Rev. 2017; 16(7): 722-729.

[6] Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009; 68(12): 1827-1832.

[7] Hervier B, Pagnoux C, Agard C, et al. French Vasculitis Study Group. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009; 68(3): 404-407.

[8] Ananthakrishnan L, Sharma N, Kanne JP. Wegener’s granulomatosis in the chest: high-resolution CT findings. Am J Roentgenol. 2009; 192(13): 676-682.

[9] Lohrmann C, Uhl M, Kotter E, et al. Pulmonary manifestations of Wegener granulomatosis: CT findings in 57 patients and a review of the literature. Eur J Radiol. 2005; 53(3): 471-477.

[10] Pretorius ES, Stone JH, Hellman DB, et al. Wegener’s Granulomatosis: CT evolution of pulmonary parenchymal findings in treated disease. Crit Rev Comput Tomogr. 2004; 45(1): 67-85.

[11] Ando Y, Okada F, Matsumoto S, et al. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51 patients. J Comput Assist Tomogr. 2004; 28(5): 710-716.

[12] Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM. 1997; 90(6): 391-399.

[13] Mohammad AJ, Bakoush O, Sturfelt G, et al. The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI). Scand J Rheumatol. 2009; 38(4): 268-275.

[14] Travis WD, Leslie KO, Beasley MB. Pulmonary vasculitis and pulmonary hemorrhage. In: Leslie KO, Wick MR. Practical pulmonary pathology: a diagnostic approach. Philadelphia (PA): Elsevier; 2018; 365-400.

[15] Tzelepis GE, Kokosi M, Tzioufas A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J. 2010; 36(1): 116-21.

[16] Terrier B, Guillevin L. Treatment of Pulmonary Vasculitis. Semin Respir Crit Care Med. 2018; 39(4): 504-10.

[17] Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. QJM.1993; 86(12): 779-89.

[18] Jennette JC, Falk RJ, Alba MA, et al. “Nomenclature of Vasculitides: 2012 Revised International Chapel Hill Consensus Conference.” Systemic Vasculitides: Current Status and Perspectives. Springer, Cham; 2016: 15-28.

[19] Hunder GG, Arend WP, Bloch DA, et al. “The American College of Rheumatology 1990 criteria for the classification of vasculitis: introduction.” Arthritis Rheum.1990; 33(8): 1065-1067.

[20] Luqmani RA, Bacon PA, Moots RJ, et al. “Birmingham vasculitis activity score (BVAS) Dim system necrotizinig vasculitis.” QJM. 1994; 87(11): 671-678.

[21] Solans-Laqué R, Fraile G, Rodriguez-Carballeira M, et al. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine. 2017; 96(8): e6083.

[22] Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012; 367(3): 214-223.

[23] Lane SE, Watts RA, Bentham G, et al. Are environmental factors important in primary systemic vasculitis? A casecontrol study. Arthritis Rheum. 2003; 48(3): 814-823.

[24] Chen M, Kallenberg CG. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev. 2010; 9(5): 293-298.

[25] Mohammad AJ, Mortensen HK, Babar J, et al. Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype. J Rheumatol. 2017; 44(10): 1458-1467.

[26] Greenan K, Vassallo D, Chinnadurai R, et al. Respiratory manifestations of ANCA-associated vasculitis. Clin Respir J 2018; 12(1): 57-61.

[27] Buda N, Masiak A, Zdrojewski Z. Utility of lung ultrasound in ANCA-associated vasculitis with lung involvement. PLoS one. 2019; 14(9): e0222189.

[28] Guneyli S, Ceylan N, Bayraktaroglu S, et al. Imaging findings of pulmonary granulomatosis with polyangiitis (Wegener’s granulomatosis): lesions invading the pulmonary fissure, pleura or diaphragm mimicking malignancy. Wien Klin Wochenschr. 2016; 128(21-22): 809-815.

[29] Comarmond C, Crestani B, Tazi A, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)- associated vasculitis: a series of 49 patients and review of the literature. Medicine. 2014; 93(24): 340-349.

[30] Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007; 66(2): 222- 227.

[31] Hosoda C, Baba T, Hagiwara E, et al. Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis. Respirology. 2016; 21(5): 920-926.

[32] Quartuccioa L, Bonda M, Isola M, et al. Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. J Autoimmun. 2020; 108: 102397.

[33] Park HJ, Jung SM, Song JJ, et al. Comparison of Radiological and Histological Findings of Lung Parenchyma in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Yonsei Med J. 2019; 60(5): 454-460.

[34] Hassan TM, Hassan AS, Igoe A, et al. Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow−up in ANCA−associated vasculitis. BMC Immunol. 2014; 15(1): 20-26.